Primary Combined Hepatocellular-Cholangiocarcinoma: A Case of Underdiagnosed Primary Liver Cancer

Review began 09/16/2021
Review ended 09/21/2021
Published 09/23/2021

© Copyright 2021

Ayas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Mohamad F. Ayas¹, Saif Affas¹, Zayd Ayas², Momal Chand³, Tarik Hadid⁴

1. Internal Medicine, Ascension St. John Hospital, Detroit, USA 2. Basic Sciences, College of Natural Sciences, University of Texas at Austin, Austin, USA 3. Pathology, Ascension St. John Hospital, Detroit, USA 4. Oncology, Ascension St. John Hospital, Detroit, USA

Corresponding author: Mohamad F. Ayas, mohamad.ayas@ascension.org

Abstract

Combined hepatocellular-cholangiocarcinoma (CHC) is a rare primary tumor of the liver. Histologically, it comprises components of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) but is associated with a worse prognosis. International guidelines regarding its management are scarce, with surgical management (major hepatectomy) being the treatment of choice. In this report, we present a challenging case of a 73-year-old male with primary CHC who was not a surgical candidate but underwent hepatic artery radioembolization instead.

Categories: Gastroenterology, Oncology

Keywords: hepatocellular carcinoma (hcc), cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, trans-arterial radioembolization, liver tumor

Introduction

Combined hepatocellular-cholangiocarcinoma (CHC) is a rare and aggressive primary hepatic malignancy consisting of combined phenotypical characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) [1]. The incidence of CHC is between 1-4.7% of all diagnosed primary liver tumors; however, it has been increasingly identified due to advances in immunohistochemistry (IHC) staining and genetic analysis [1,2,3], with a reported incidence of 0.4-14.2% across a number of studies. Despite being a distinct entity, there are no clear guidelines for managing these tumors, and surgical resection is the preferred treatment, with high curative rates [1,4,5]. However, in inoperable patients or those with tumor recurrence, nonsurgical management could be used, which includes transarterial chemoembolization (TACE), transarterial radioembolization (TARE), hepatic arterial infusion chemotherapy, and systemic chemotherapy [1]. We present a case of CHC in a 73-year-old male who was treated with TARE.

Case Presentation

A 73-year-old man with a past medical history of alcohol dependence presented with a two-week history of the right upper quadrant (RUQ) abdominal pain that was sharp in nature. The patient denied any nausea, vomiting, or recent change in bowel habits. He also denied any weight loss or any family history of malignancies. Vital signs were within normal limits. Abdominal examination showed tenderness in the RUQ, with a negative Murphy sign, and no hepatosplenomegaly was appreciated. Laboratory findings showed a hemoglobin of 9.9 gm/dl, an international normalized ratio (INR) of 1.31, total bilirubin of 2.2 mg/dl with a direct bilirubin of 0.7 mg/dl, alkaline phosphatase (ALP) of 334 IU/L, aspartate aminotransferase (AST) of 49 IU/L, and normal alanine aminotransferase (ALT) levels, with a negative hepatitis B and C panel. An abdominal ultrasound (US) was done, which showed an enlarged liver of 17.7 cm with two hypoechoic lesions within the right hepatic lobe. The patient then underwent a CT abdomen with intravenous (IV) contrast that did not demonstrate any liver lesions. Due to equivocal findings on the US and CT abdomen, the patient underwent an MRI of the abdomen with and without contrast, which showed a conglomerated 6.4 x 8-cm mass in the left lobe of the liver, possibly suggesting a hepatoma or neoplastic mass (Figure 1), with mild dilatation of the biliary ducts in the left lower lobe, and normal common hepatic and common bile ducts. Subsequently, an Oncology consult was requested.

Tumor markers alpha-fetoprotein (AFP) and CA 19-9 were both negative. The patient then underwent a CT-guided liver biopsy. Pathologic analysis showed foci of tumor cells positive for hepatocyte antigen staining, with another focus consisting of closely packed tubules positive for CK7 and negative for hepatocyte antigen, consistent with CHC (Figures 2, 3). The patient at that time was deemed a poor surgical candidate and underwent nuclear arterial mapping followed by yttrium-90 radioembolization of the left hepatic artery. However, during the follow-up, MRI for restaging was done and showed increased right hepatic lobe tumor burden as well as complete venous thrombosis of the portal vein extending to the superior mesenteric vein. Due to the rapidly worsening performance status, the patient was not considered a candidate for further treatment and was later transferred to hospice.

How to cite this article

Ayas M F, Affas S, Ayas Z, et al. (September 23, 2021) Primary Combined Hepatocellular-Cholangiocarcinoma: A Case of Underdiagnosed Primary Liver Cancer. Cureus 13(9): e18224. DOI 10.7759/cureus.18224

FIGURE 1: MRI showing a non-uniform enhancement of 6.4 x 8-cm mass in the left lobe of the liver (blue arrow)

MRI: magnetic resonance imaging

FIGURE 2: Hepatocellular carcinoma component, with loss of cellular architectural organization with eosinophilic cytoplasm

FIGURE 3: Cholangiocarcinoma component of the same tumor with vesicular cytoplasm; increased nuclear-to-cytoplasmic ratio

Discussion

CHC is a primary liver tumor with a vast histological spectrum and multiple classifications, making it a diagnostic challenge to pathologists, radiologists, and treating clinicians. It was first classified in 1949 by

Allen and Lisa into three histological types; A, B, and C as described in Table 1 [1,2]. Subsequently, Goodman et al. re-classified CHC in 1985 into three separate entities: collision (type I), transitional (type II), and fibrolamellar (type III) (Table 1) [1,2,6]. Finally, in 2010, the World Health Organization (WHO) classified CHC into two types: classical and stem cell type, as described in Table 2 [3,7].

CHC should be suspected in patients with a discordant pattern between imaging and tumor markers [2,3]. To meet the diagnostic criteria, the sample must show indisputable evidence of hepatocellular and biliary differentiation. Thus, adequate tissue samples are needed to recognize the possible presence of both histopathologies. Furthermore, a core needle biopsy is preferred over fine-needle aspiration, in order to ensure adequate tissue sampling [2], and definitive diagnosis can only be made after a histological assessment of a representative biopsy and IHC staining [1].

According to Wang et al., a retrospective study of 642 patients with CHC between 2000-2014 was done and showed that the mean age at diagnosis was 62 years, with a male and Caucasian predominance [8]. Risk factors included alcoholism, male gender, hepatitis B virus (HBV), and hepatitis C virus (HCV) [2,9].

The consensus method for the treatment of CHC is hepatic resection with or without lymph node dissection [2], as it was observed that patients who did not undergo surgery had lower survival rates [10]. The one-year survival rate for CHC was found to be 41.9%, and the five-year survival rate was 17.7%, with a median survival rate of eight months [10]; however, there was a significant improvement in patients who underwent surgical resection [8]. There are conflicting study findings regarding the role of liver transplantation (LT) in CHC; however, most studies have documented positive outcomes, with a reported 40% five-year overall survival rate in some studies [11]. Moreover, one study has shown no difference in the overall three-year survival rate when comparing those with CHC undergoing surgical resection vs. those undergoing LT [12].

Although surgical resection is the only curative option, the use of TACE, TARE, and systemic chemotherapy can be considered for those with inoperable tumors [2]. The use of TARE has been minimally studied in the treatment of inoperable CHC. According to a study by Badar et al., a retrospective analysis involving 10 patients with CHC between 2013-2019 receiving TARE therapy, the median overall survival rate was 15.2 months [13]. Moreover, a similar study by Fowler et al. examined six patients with CHC who underwent TARE, and they had a median overall survival rate of 16 months [14]. Unfortunately, in our case, the patient had an overall survival rate of three months status post TARE therapy.

Allen and Lisa [1,2]	Tumor description	Goodman et al. [1,2,6]	Tumor description
Type A	HCC and CC at different sites but within the same liver	Type I	Collision tumor or an apparently coincidental occurrence of HCC and CC within the same liver
Type B	HCC and CC adjacent to each other	Type II	Transitional tumor in which there is a transition from HCC elements to CC elements
Type C	HCC and CC combined within the same tumor	Type III	Fibrolamellar tumor that resembles the fibrolamellar subtype of HCC but containing mucin-producing pseudoglands

TABLE 1: Classification of CHC

HCC: hepatocellular carcinoma; CC: cholangiocarcinoma; CHC: combined hepatocellular-cholangiocarcinoma

WHO classification [3,7]	Tumor description
Classical type	Characterized by areas of typical HCC intermixed with CC with the presence of transition zones with intermediate cellular
Stem cell type	Typical Nest of mature hepatocytes surrounded by peripheral clusters of small cells exhibiting morphological and immunohistochemical characteristics of progenitor cells
	Intermediate Cells with intermediate features between hepatocytes and cholangiocytes with immunohistochemical markers of both histological entities arranged in trabeculae, solid nests, or strands
	CLC Cells morphologically mimicking cholangioles arranged in a tubular anastomosing (antler-like) pattern within a dense, sclerotic stroma and expressing progenitor/stem cell markers. Fibrolamellar tumor that resembles the fibrolamellar subtype of HCC but containing mucin-producing pseudoglands

TABLE 2: Classification of CHC by the World Health Organization

WHO: World Health Organization; HCC: hepatocellular carcinoma; CC: cholangiocarcinoma; CLC: cholangiocellular; CHC: combined hepatocellular-cholangiocarcinoma

Conclusions

CHC is a rare primary liver tumor, and preoperative clinical diagnosis is extremely difficult, making it an often underdiagnosed entity. Histology and immunohistopathology are the only ways for a definitive diagnosis. Surgical hepatectomy with hilar lymph node resection is the only curative treatment; however, other treatment options such as TACE, TARE, and/or systemic chemotherapy should be considered in inoperable patients as described in our case.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We would like to thank Dr. Sindhu Malapati for her contribution in the management and care of the patient throughout the hospital stay.

References

1. Stavra C, Rush H, Ross P: Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. *J Hepatocell Carcinoma*. 2019, 6:11-21. [10.2147/JHC.S159805](#)
2. Gera S, Ettel M, Acosta-Gonzalez G, Xu R: Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. *World J Hepatol*. 2017, 9:300-9. [10.4254/wjh.v9.i6.300](#)
3. Chi CT, Chau GY, Lee RC, et al.: Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection. *J Formos Med Assoc*. 2020, 119:125-33. [10.1016/j.jfma.2019.02.012](#)
4. Trikalinos NA, Zhou A, Doyle MB, et al.: Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience. *J Natl Compr Canc Netw*. 2018, 16:1193-9. [10.6004/jnccn.2018.7053](#)
5. Wang AQ, Zheng YC, Du J, et al.: Combined hepatocellular cholangiocarcinoma: controversies to be addressed. *World J Gastroenterol*. 2016, 22:4459-65. [10.3748/wjg.v22.i18.4459](#)
6. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L: Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. *Cancer*. 1985, 55:124-35. [10.1002/1097-0142\(19850101\)55:1<124::aid-cnrcr2820550120>3.0.co;2-z](#)
7. Bosman FT, Carneiro F, Hruban R, Theise ND: WHO Classification of Tumours of the Digestive System . IARC Press, Lyon, France; 2010.
8. Wang J, Li E, Yang H, et al.: Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends. *World J Surg Oncol*. 2019, 17:43. [10.1186/s12957-019-1586-8](#)
9. Zhang ZG, Chen Y, Ji R, et al.: Synchronous cancers of gallbladder carcinoma and combined hepatocellular

- cholangiocarcinoma: an unusual case and literature review. *BMC Cancer*. 2018, 18:1046. [10.1186/s12885-018-4969-2](https://doi.org/10.1186/s12885-018-4969-2)
10. Ramai D, Ofosu A, Lai JK, Reddy M, Adler DG: Combined hepatocellular cholangiocarcinoma: a population-based retrospective study. *Am J Gastroenterol*. 2019, 114:1496-501. [10.14309/ajg.0000000000000326](https://doi.org/10.14309/ajg.0000000000000326)
 11. Vilchez V, Shah MB, Daily MF, et al.: Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. *HPB (Oxford)*. 2016, 18:29-34. [10.1016/j.hpb.2015.10.001](https://doi.org/10.1016/j.hpb.2015.10.001)
 12. Groeschl RT, Turaga KK, Gamblin TC: Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. *J Surg Oncol*. 2013, 107:608-12. [10.1002/jso.23289](https://doi.org/10.1002/jso.23289)
 13. Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, Ahmed O: Yttrium-90 radioembolization therapy for combined hepatocellular and cholangiocarcinoma. *Gastrointest Tumors*. 2020, 7:144-50. [10.1159/000508386](https://doi.org/10.1159/000508386)
 14. Fowler K, Saad NE, Brunt E, et al.: Biphenotypic primary liver carcinomas: assessing outcomes of hepatic directed therapy. *Ann Surg Oncol*. 2015, 22:4130-7. [10.1245/s10434-015-4774-y](https://doi.org/10.1245/s10434-015-4774-y)